As of 2026-05-31, the Intrinsic Value of Eyebright Medical Technology Beijing Co Ltd (688050.SS) is 78.45 CNY. This 688050.SS valuation is based on the model Discounted Cash Flows (Growth Exit 10Y). With the current market price of 42.42 CNY, the upside of Eyebright Medical Technology Beijing Co Ltd is 84.90%.
The range of the Intrinsic Value is 37.34 - 384.14 CNY
Based on its market price of 42.42 CNY and our intrinsic valuation, Eyebright Medical Technology Beijing Co Ltd (688050.SS) is undervalued by 84.90%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (26.06) - (10.13) | (12.03) | -128.4% |
| DCF (Growth 10y) | 37.34 - 384.14 | 78.45 | 84.9% |
| DCF (EBITDA 5y) | 99.41 - 140.35 | 117.19 | 176.3% |
| DCF (EBITDA 10y) | 204.88 - 344.47 | 263.45 | 521.0% |
| Fair Value | 34.26 - 34.26 | 34.26 | -19.25% |
| P/E | 30.80 - 39.19 | 35.96 | -15.2% |
| EV/EBITDA | 17.05 - 38.13 | 25.67 | -39.5% |
| EPV | (0.24) - 4.24 | 2.00 | -95.3% |
| DDM - Stable | 12.77 - 114.78 | 63.77 | 50.3% |
| DDM - Multi | 48.04 - 340.91 | 84.70 | 99.7% |
| Market Cap (mil) | 8,204.03 |
| Beta | 1.41 |
| Outstanding shares (mil) | 193.40 |
| Enterprise Value (mil) | 9,503.03 |
| Market risk premium | 6.13% |
| Cost of Equity | 8.29% |
| Cost of Debt | 5.00% |
| WACC | 8.03% |